Analysis of R213R and 13494 g→a polymorphisms of the p53 gene in individuals with esophagitis, intestinal metaplasia of the cardia and Barrett’s Esophagus compared with a control group by Pilger, Diogo André et al.
RESEARCH ARTICLE
Analysis of R213R and 13494 g ﬁ a polymorphisms
of the p53 gene in individuals with esophagitis, intestinal
metaplasia of the cardia and Barrett’s Esophagus compared
with a control group
Diogo Andre ´ Pilger Æ Patrı ´cia Luciana da Costa Lopez Æ
Fa ´bio Segal Æ Sandra Leistner-Segal
Received: 18 December 2006/Accepted: 2 May 2007/Published online: 25 May 2007
  Springer Science+Business Media B.V. 2007
Abstract Protein p53 is the tumor suppressor involved in
cell cycle control and apoptosis. There are several poly-
morphisms reported for p53 which can affect important
regions involved in protein tumor suppressor activity.
Amongst the polymorphisms described, R213R and 13949
g ﬁ a are rarely studied, with an estimate frequency not
yet available for the Brazilian population. The purpose of
this study was to investigate the genotype and allele fre-
quencies and associations of these polymorphisms in a
group of patients with altered esophageal tissue from South
Brazil and compare with the frequency observed for a
control population. A total of 35 patients for R213R and 45
for 13494 g ﬁ a polymorphisms analysis with gastro-
esophageal reﬂux disease (GERD) symptoms diagnosed by
upper digestive endoscopy and conﬁrmed by biopsy were
studied. For both groups, 100 controls were used for
comparison. Loss of heterozygosity (LOH) was also ana-
lyzed for a selected group of patients where normal and
affected tissue was available. There was one patient with
Barrett’s Esophagus (BE) showing LOH for R213R out of
two heterozygous samples analyzed and two patients
(esophagitis and BE) for 13494 g ﬁ a polymorphism. We
also aimed to build a haplotype for both polymorphisms
collectively analyzed with R27P polymorphism, previously
reported by our group. There were no signiﬁcant differ-
ences in allele and genotype distribution between patients
and controls. Although using esophagitis, intestinal meta-
plasia of the cardia and BE samples, all non-neoplastic
lesions, we can conclude that these sites do not represent
genetic susceptibility markers for the development and
early progression of GERD to BE and esophageal cancer.
Additional studies are required in order to investigate other
determiners of early premalignant lesions known to pre-
dispose to esophageal cancer.
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Introduction
Barrett’s Esophagus (BE) is a complication of the gastro-
esophageal reﬂux disease being an acquired premalignant
disorder that predisposes to the development of adenocar-
cinoma of the esophagus in 10% of the patients. It is also
used as a model to investigate the order of genetic events in
neoplastic progression (Audre ´zet et al. 1996).
The progressive evolution of the normal esophageal
epithelium into the columnar-type epithelium in BE is
characterized by a complex sequence of events beginning
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(esophagitis), resulting from chronic reﬂux, followed by
intestinal metaplasia of the cardia (IMC) and BE,
increasing levels of dysplasia, and adenocarcinoma. This
process is modulated by environmental stimuli and genetic
predisposition that result in genomic instability. Cells with
multiple developed genetic abnormalities result in cellular
clones with acquired genetic errors. Some clones acquire
proliferative advantage and may develop capacity for
invasion, resulting in neoplasia (Blount et al. 1990).
Several studies have focused on the metaplasia-adeno-
carcinoma transition while little is still known with respect
to molecular factors that contribute to the development of
alterations preceding intestinal metaplasia (Reid et al.
1987; Rabinovitch et al. 1989; Reid et al. 1992). The
activity of several genes has been used to pinpoint altera-
tions in the progression that leads to dysplasia and ade-
nocarcinoma.
Neshat et al. (1994) described the molecular alterations
related to esophagus neoplasia. Gene mutations in the tu-
mor-suppressing p53 gene were the abnormalities most
commonly reported. The incidence of mutations tends to
increase with the metaplasia-dysplasia-adenocarcinoma
progression, ranging from rare in non-dysplastic epithelium
to up to 90% in adenocarcinoma (Neshat et al. 1994;
Fitzgerald 2005).
More than 90% of the mutations described for the p53
gene occur between exons 4 and 9, which encompass
protein domains II-V. This region is evolutionarily highly
conserved and involves the DNA-binding domain, essential
for the activity of p53 (Donehower and Bradley 1993;
Soussi 1996).
p53 gene mutations can damage its DNA-binding or
transactivation functions, thereby inhibiting its key role in
the cell cycle control. In the majority of these cases where
the mutation is recessive, tumor cells often retained only
the mutated allele and lose the wild type, while blood cells
harbor both alleles. This loss is named loss of heterozy-
gosity (LOH) (Baccouche et al. 2003).
Chromosomal regions with frequent LOH may point out
those genes with higher susceptibility and help to under-
stand the molecular events involved in carcinogenesis (Hu
et al. 1999).
Mutations in tumor suppressor p53 gene have been de-
tected in more than 25% of patients with Barrett’s meta-
plasia submitted to endoscopy and in more than 75% of
Barrett’s adenocarcinomas (Aldulaimi and Jankowski
1999).
In addition to cancer-associated mutations, at least 200
polymorphisms have already been described at the p53
gene, both in coding and noncoding regions (IARC, NCI,
NCBI, 2007), although most of them are located in introns
outside the consensus region of splicing sites.
Studies indicate that the preferential polymorphic alleles
of the gene may be involved with susceptibility and pre-
disposition to cancer. (Soulitzis et al. 2002; Olschwang
et al. 1991; Baccouche et al. 2003).
Among these, the polymorphism R213R in exon 6 and
the polymorphism 13949 g ﬁ a in intron 6 are rarely
studied, with an estimate frequency not yet available for
the Brazilian population (IARC). The R213R polymor-
phism retains the arginine amino acid, the most frequent
codon being CGA and the polymorphic, CGG. The poly-
morphism 13494 g ﬁ a shows adenine replacing guanine.
No phenotypic differences were reported in both cases.
Our study aimed to estimate the frequency of R213R
and 13494 g ﬁ a polymorphisms in control individuals,
who represent the population of Porto Alegre, and in
individuals with alterations in the esophageal tissue from
the southernmost region of Brazil. In addition, we studied
the potential association between the frequencies of this
polymorphism in these two groups. The analysis of normal
and altered tissue obtained from some of the patients al-
lowed us to check for the existence of loss of heterozy-
gosity in these regions of the gene. Furthermore, it also
purports to build a haplotype for both polymorphisms
collectively analyzed with the R27P polymorphism of exon
4 of the TP53, previously analyzed by our group (Leistner-
Segal et al. 2006).
Materials and methods
Study design
This is a case control study designed to determine the
relative frequency of three p53 polymorphisms in controls
versus patients with GERD and complications such as BE.
In addition, the study was designed to identify LOH at
these loci in patients.
Patients and controls
A total of 35 patients (17 female and 18 male; ages ranging
between 23 years and 82 years; average of 51.1 years)
with gastroesophageal reﬂux disease (GERD) symptoms
diagnosed by upper digestive endoscopy and conﬁrmed by
biopsy were analyzed for the R213R polymorphism, while
for the 13494 g ﬁ a polymorphism analysis a total of 45
individuals (22 female and 23 male; ages ranging between
23 years and 82 years; average of 51.4 years) were used.
The biopsies were analyzed according to Segal et al. 2004.
For controls, 100 donor samples from Hospital de Clı ´nicas
of Porto Alegre Blood Bank were analyzed. This project
was approved by the Ethic Committee of HCPA (03191)
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All procedures were performed with written informed
consent of the patients.
DNA extraction
Ten milliliters of peripheral blood in EDTA was withdrawn
from controls and patients and DNA was isolated using the
salting out procedure described by Miller et al. (1988). In
addition, tissue from the lesion site was obtained by biopsy
at endoscopy from patients showing esophageal alterations.
DNA extraction from tissue was performed freshly, carried
out as previously described (Leistner-Segal et al. 2006).
Because we did not perform laser microdissection in the
affected tissue, it is possible that these samples may also
contain cells carrying normal DNA.
Conditions for polymerase chain reaction (PCR)
The long PCR technique of exons 5 to 8 of the p53 gene
was set as standard. Hence, exon 5 forward (5¢CTGCCC
TGACTTTCAACTCTG3¢) and exon 8 reverse (5¢TGCA
CCCTTGGTCTCCTCCAC3¢) primers were used, accord-
ing to Segal et al. 2004 (31). Ampliﬁcations were carried
out using approximately 200 ng DNA, 1 U Taq DNA
Polymerase (Invitrogen
TM), 5 ll enzyme buffer (Tris-HCl
200 mM, KCl 500 mM), 5 ll dNTP 0.2 mM (Invitro-
gen
TM), 1.5 ll MgCl2 (50 mM), and 1.0 ll of each speciﬁc
primer at a concentration of 20 pmol for a ﬁnal reaction
volume of 50 ll.
PCR conditions were: initial denaturation at 94 C for
3 min., followed by 35 cycles of 40 s, with 94 Co f
denaturation, 55 C of annealing and extension at 72 C, and
ﬁnal extension of 72 C for 10 min. The ampliﬁed fragment
of 1619 pb was submitted to 1.5% agarose gel electro-
phoresis and visualized through ethidium bromide staining.
Digestion with restriction enzymes
R213R (exon 6) polymorphism: to identify the R213R
polymorphism, digestion of the long PCR product was
carried out using TaqI (New England BioLabs
TM) enzyme
to cleave the T¢CGA site, according to the manufacturer’s
instructions. The digestion used 10 ll of the PCR product
and 2 U of the enzyme in a total ﬁnal volume of 30 ll. The
reaction was kept at 65 C in a thermocycler for 2 h and
30 min. Fragments resulting from cleavage of the PCR
product with the TaqI enzyme are 385, 309 and 925 bp in
the presence of the CGA sequence, and 694 and 925 bp in
the presence of the CGG sequence.
13494 g ﬁ a (intron 6) polymorphism: to identify the
13494 g ﬁ a polymorphism, digestion on the long PCR
product was carried out using the MspI (New England
BioLabs
TM) enzyme to cleave the C¢CGG site, according to
the manufacturer’s instructions. The digestion used 10 ll
of the PCR product and 2 U of the enzyme in a total ﬁnal
volume of 30 ll. The reaction was incubated at 37 C in dry
bath. Fragments resulting from cleavage of the PCR
product with the MspI enzyme are 124, 356, 276, 299, 168,
276 and 120 bp in the presence of the CGG sequence, and
124, 632, 299, 168, 276 and 120 bp in the presence of the
CAG sequence.
Both digestion products were subject to electrophoresis
in 3% agarose gel. The band pattern found is visualized in
Fig. 1.
The statistical analysis of results was performed using a
Pearson’s chi-square test in the MedCalc
TM software.
Loss of heterozygosity analysis
For this study, the DNA extracted from blood and affected
tissue of the same patient was analyzed. Only individuals
who presented a heterozygous pattern in their blood were
considered (n = 2 for the R213R polymorphism and n =1 2
for the 13494 g ﬁ a polymorphism), respectively 8% and
33% of the sample for each polymorphism.
Results
Clinical signs
All patients showed signs of GERD. For R213R poly-
morphism analysis, 20% (7/35) showed esophagitis, 37.1%
(13/45) showed IMC and 42.9% (15/35) showed BE. For
the 13494 g ﬁ a polymorphism, 27% (12/45) showed
esophagitis, 37.8% (17/45) IMC and 35.6% (16/45) BE.
Long PCR technique standardization
The presented methodology proved to be adequate for
ampliﬁcation of a relatively long segment involving four
signiﬁcant exons for the p53 protein function, as shown in
Fig. 1.
Identiﬁcation of R213R (exon 6) polymorphism
In both groups of patients and controls a predominance of
the allele (A) was noticed, with no homozygosis for the
polymorphic allele (G) being reported. This was only found
in heterozygosis in two individuals in the patients group
and four in the control group, as shown on Table 1. The
frequencies found for this polymorphism were notably
similar in both groups, without signiﬁcant difference for
Genomic Med. (2007) 1:57–63 59
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respectively).
The two patients presenting the allele (G) in heterozy-
gosis showed IMC and BE.
These results were compared with literature data and no
signiﬁcant difference was observed among frequencies of
the polymorphic allele (P = 0.978) (Akar et al. 1999).
When comparing with an American population, no sig-
niﬁcant difference was found, not even in comparison with
Afro-American, Caucasian and Hispanic subpopulations
within the same study (P = 0.913, P = 0.726, P = 0.736
and P = 0.687, respectively) (NCI).
Figure 1 shows the results of TaqI digestion, highlight-
ing the possible alleles.
Identiﬁcation of the 13494 g ﬁ a (intron 6)
polymorphism
In both groups of patients and controls predominance of the
allele (G) was observed, with homozygosis found for the
polymorphic allele (A) in four individuals from the control
group and none in the patient group, as shown in Table 2.
Similar to the R213R polymorphism, the frequency anal-
ysis of the 13494 g ﬁ a polymorphism did not present a
signiﬁcant difference when comparing the patients with the
control group for both the genotypic and allelic analysis
(P = 0.607 and P = 0.395, respectively).
The patients that present the polymorphic allele (A)
showed esophagitis (4/45), IMC (5/45) and BE (3/45).
When the frequencies found in our population were
superimposed over the literature data, a signiﬁcant differ-
ence was noted. The population analyzed in the Akar et al.
1999 study showed a frequency of 0.3 polymorphic alleles,
thus differing from the ﬁndings in this study, which were
0.165 (P = 0.008).
When comparing to an American population, no sig-
niﬁcant difference was found, not even in comparison with
Afro-American, Caucasian, Hispanic and Paciﬁc Coast
subpopulations within the same study (P = 0.928,
P = 0.404, P = 0.467 and P = 0.723, respectively) (Shah-
een and Ransohoff 2002).
Figure 1 shows the result of MspI digestion, highlight-
ing the possible alleles.
Loss of heterozygosity
The analysis consisted in pairs of blood and tissue samples
from the same patient.
Fig. 1 Agarose gel (3.0%)
showing long PCR results and
digestions carried out with TaqI
and MspI. Position 8 shows the
100 bp molecular weight
marker. Position 1 shows the
long PCR product concerning
exons 5 to 8 in the TP53.
Positions 2, 3 and 4 show the
allelic patterns AA and AG for
the R213R polymorphism.
Positions 5, 6 and 7 show the
allelic patterns AA, AG and GG
for the 13494 g ﬁ a
polymorphism
Table 1 Genotype and allele
frequency of the R213R
polymorphism in patients and
controls
Group Genotype Allele
AA AG GG A G
Controls (n = 100) 96 (0.960) 4 (0.040) 0 (0.00) 196 (0.980) 4 (0.02)
Patients (n = 35) 33 (0.943) 2 (0.057) 0 (0.00) 68 (0.971) 2 (0.028)
Table 2 Genotype and allele
frequency of the 13494g ﬁ a
polymorphism in patients and
controls
Group Genotype Allele
AA AG GG A G
Controls (n = 100) 4 (0.040) 25 (0.250) 71 (0.710) 33 (0.165) 167 (0.835)
Patients (n = 45) 0 (0.000) 12 (0.267) 33 (0.733) 12 (0.133) 78 (0.867)
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samples analyzed, was found for the R213R polymor-
phism, a patient carrying BE. For the 13494 g ﬁ a poly-
morphism, LOH was conﬁrmed in two patients (7.4%), a
carrier of esophagitis and another one BE. The polymor-
phic allele present in the peripheral blood sample was not
kept in the tissues of these two patients, conﬁrming the
stress in such tissues even when the wild allele was pre-
served.
Haplotype analysis for the R213R, 13494 g ﬁ a and
R72P polymorphisms
The R213R and 13494 g ﬁ a polymorphisms were jointly
analyzed with the R27P polymorphism, previously re-
ported by us using the same group of patients (Leistner-
Segal et al. 2006). Analysis consisted of 26 patients for the
three polymorphisms collectively. The genotypic patterns
obtained are shown in Table 3.
The analysis demonstrates the conserved haplotype
[AA, GG, RR] for the three polymorphisms. The alleles
present in the previous haplotype are the most frequent in
the general population, except for the R72P polymorphism
that in the previous analysis carried out by our group
showed predominance of the PR genotype.
In the allele frequency analysis there were no signiﬁcant
difference between the three histological types (esophagi-
tis, IMC and BE) for none of the polymorphisms, R213R,
13494 g ﬁ a and R72P (P = 0.7600, P = 0.8438 and
P = 0.8557, respectively).
Discussion
The loss of cell cycle control and the progression to cancer
in TP53 events in exons 5–8 are already well established.
The functional signiﬁcance and the frequency of poly-
morphisms in these regions still remain unknown. It is
believed that they may contribute to a higher susceptibility
(or resistance) to developing cancer (Vos et al. 2003).
A consistent association between these polymorphisms
and several types of human neoplasias may serve as
argument supporting such sites as susceptibility determin-
ers (IARC). Furthermore, mutations in ﬂanking regions of
these exons are probably rare in spite of the biological
signiﬁcance they present.
The genes involved with tumor genesis are potential
molecular markers associated to susceptibility to cancer.
We thus investigated the relationship linking the R213R
and 13494 g ﬁ a polymorphisms of the p53 gene and the
premalignant esophageal alterations (esophagitis, IMC and
BE). Also, countless studies indicate an association be-
tween the R72P polymorphism at exon 4 of TP53 and the
increased risk of developing neoplasias (Malcolm et al.
2000; Gottschlich et al. 2000; Nakano et al. 2000; Lacerda
et al. 2005). Hence, we also carried out a joint analysis of
the three polymorphisms described by means of a haplo-
type.
In the present study the genotypic distribution of the
R213R and 13494 g ﬁ a polymorphisms are in agreement
with the Hardy-Weinberg equilibrium in the patient group
as well as in the control group. The genotypic analysis of
both polymorphisms did not present a signiﬁcantly different
allele distribution compared to the control samples, which
leads us to conclude that there is no correlation, at these
stages, between such molecular ﬁndings and the histologi-
cal types, although a strong ethnic variation with regard to
the prevalence of these two polymorphisms (Leistner-Segal
et al. 2006, Segal et al. 2004) is known to exist.
While analyzing the R213R polymorphism, Mazars
et al. 1992 obtained results similar to ours for ovarian
carcinoma and blood bank donor controls with prevalence
Table 3 Haplotype analysis involving R213R, 13494 g ﬁ a and
R72P polymorphisms of TP53
Patient R213R 13494 g ﬁ a R72P Histological
type
Case 1 AA GG PR BE
Case 2 AA AG RR BE
Case 3 AA AG RR BE
Case 4 AA GG PR BE
Case 5 AA AG PR IMC
Case 6 AA GG PR ESOPHAGITIS
Case 7 AA AG RR ESOPHAGITIS
Case 8 AA GG RR IMC
Case 9 AA GG RR BE
Case 10 AA GG RR IMC
Case 11 AA GG PR BE
Case 12 AA GG PR BE
Case 13 AA AG PR IMC
Case 14 AA GG RR ESOPHAGITIS
Case 15 AA AG PR IMC
Case 16 AA GG RR IMC
Case 17 AG AG PR BE
Case 18 AA GG RR BE
Case 19 AG GG RR IMC
Case 20 AA AG PP ESOPHAGITIS
Case 21 AA GG RR ESOPHAGITIS
Case 22 AA GG RR IMC
Case 23 AA GG RR BE
Case 24 AA GG PR BE
Case 25 AA GG PR IMC
Case 26 AA GG PR BE
IMC: intestinal metaplasia of cardia, BE: Barrett ´s Esophagus
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123of 3% and 2.6% for the polymorphic allele, respectively. In
the analysis of the 13494 g ﬁ a polymorphism for gas-
trointestinal and breast tumors, Peller et al. 1995 also
found results similar to ours, with frequencies of the het-
erozygous AG genotype of 32% and 68% for homozygous
GG genotypes, for the patient group. These results match
the allele frequency described by Chumakov and Jenkins
1991, which was 31% for the AG genotype, and 69% for
the GG genotype.
It was anticipated that there would be a smaller pro-
portion of the polymorphism in the exon 6 since the coding
sequence is more conserved than the intronic region,
mainly because the region in which this polymorphism is
located carries great importance to the activity of the p53
protein. Eventual differences detected in several studies
may be explained by ethnic differences between the groups
analyzed (Brenna et al. 2004). Different genetic attributes
may bestow protection against or risk for developing can-
cer in populations of diverse ancestries (Rocha 2005).
However, other reasons such as sample size, DNA source,
and techniques employed should also be taken into con-
sideration (Brenna et al. 2004).
In the combined analysis with the R72P polymorphism
previously studied by our group, a similar frequency was
observed in both controls and patients. According to
Table 3, the most frequent haplotype was [AA, GG, RR]
which occurred in 34.6% of analyzed patients. Since the
most frequent haplotype is the same in patient and control
groups, we may think again that the absence of association
between these three polymorphisms and the esophageal
alterations stems from the fact that molecular alterations
can only be identiﬁed in more advanced stages of the
normal tissue-metaplasia-adenocarcinoma progression.
The LOH ﬁndings are in agreement with the occurrence
of genomic instability seen in various types of cancer, and
serve as encouragement to the understanding of DNA re-
pair processes in replication and recombination events
(Thiagalingam et al. 2002). All tissue samples presented
the wild allele indicating that cells carrying the analyzed
polymorphisms were heterozygotic or that many normal
cells (lacking polymorphism) were present in the tissue
from which DNA was extracted (Campomenosi et al. 1996,
Doak et al. 2003). This fact may have minimized the LOH
ﬁndings in our study.
The allelic loss associated to esophageal carcinogenesis
was found by Kawaguchi for the codon 72 polymorphism
(Kawaguchi et al. 2000). Abnormalities involving the
TP53 are common with esophageal adenocarcinoma and
have been detected in pre-malignant tissues surrounding
the esophageal cancer (Prevo et al. 1999; Reid et al. 2001).
Neshat et al. 1994 reported molecular and genomic alter-
ations identifying LOH in 94% of Barrett cancers and 88%
of mutations in the TP53. Allelic loss of 17p has been
detected in initial stages of high-degree metaplasia and
dysplasia, leading to aneuploidy and suggesting that inac-
tivation of the TP53 is a ﬁrst step in carcinogenesis. Both
cases of LOH located in the intron 6 reinforce the data in
literature for these events being found in altered tissues and
also highlight the presence of alterations within the non-
coding region. Such alterations may alter the phenotype of
the protein being coded and are of considerable value in
understanding the genic expression.
According to Campomenosi et al. 1996 the association
of the molecular ﬁndings with the histological type occurs
upon development of the BE since the type I metaplasia
(common in BE) would be more responsive to damage
caused by GERD and therefore more prone to developing
aneuploidies than the tissues analyzed in our study (Li
et al. 2005). Without doubt, this could provide an expla-
nation to the fact that our results do not differ from those in
the control population, since the tissues assayed were in
early stages of BE development.
There is increasing evidence that new mechanisms
including mutation in splicing sites, introns and promoter
regions are involved in the genic expression. Identiﬁcation
of these alterations may help select patients with a higher
risk of developing cancer, allowing optimization of treat-
ments (Lacerda et al. 2005).
Considering our data regarding the incidence of alleles,
genotypes and haplotypes of the R213R, 13494 g ﬁ a and
R72P polymorphisms of the p53 gene in patients and
controls, we can suggest that these three sites do not rep-
resent genetic susceptibility determiners to esophagitis,
intestinal metaplasia of the cardia and BE. Additional
studies are required in order to investigate these three
polymorphisms in advanced stages of carcinogenesis.
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